David Allison
SlowingNamed in filings at Westlake Biopartners
- Board seats filed
- 7
- Named on a board
- 1
all filings on record
Named in filings at Westlake Biopartners
all filings on record
last 24 months
from a verified or cited source
| Arpeggio Biosciences | Biotech & pharma | November 2025 | None on file |
| Portal Instruments | Medical devices | April 2022 | None on file |
| Neurogastrx | Biotech & pharma | June 2021 | None on file |
| Soteria Biotherapeutics | Biotech & pharma | May 2021 | None on file |
| Albamunity | Not yet classified | July 2020 | Partners Innovation |
| IMPEL NEUROPHARMA | Biotech & pharma | June 2019 | None on file |
| Ceterix Orthopaedics | Medical devices | December 2016 | New Enterprise Associates, Pivotal bioVenture Partners, Versant Side, Versant Venture Capital, Versant Venture V AIV, Versant Voyageurs |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name David Allison on the board, based on 6 filed seats with a verified or cited source.
1 more filed seat not yet classified, left out of the shares above.